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Protein–protein interactions as targets
for small-molecule therapeutics
in cancer
Alex W. White*, Andrew D. Westwell and Ghali Brahemi
Small-molecule inhibition of the direct protein–protein interactions that mediate
many important biological processes is an emerging and challenging area in
drug design. Conventional drug design has mainly focused on the inhibition of a
single protein, usually an enzyme or receptor, since these proteins often contain
a clearly defined ligand-binding site with which a small-molecule drug can be
designed to interact. Designing a small molecule to bind to a protein–protein
interface and subsequently inhibit the interaction poses several challenges,
including the initial identification of suitable protein–protein interactions, the
surface area of the interface (it is often large), and the location of ‘hot spots’
(small regions suitable for drug binding). This article reviews the general approach
to designing inhibitors of protein–protein interactions, and then focuses on recent
advances in the use of small molecules targeted against a variety of protein–
protein interactions that have therapeutic potential for cancer.
Fundamental processes in living cells, such
as intracellular signal transduction and
maintenance of cytoskeletal architecture, are
largely controlled by proteins, often acting in
concert with other protein partners through
protein–protein interactions (PPIs).
Inappropriate protein–protein recognition can
contribute fundamentally to many diseases,
including cancer. Selective, small-molecule
modulation of PPIs is therefore an area of
growing interest to pharmaceutical science
(Refs 1, 2, 3, 4, 5, 6, 7, 8, 9).
Despite the pivotal role of PPIs in many
processes relevant to cancer development,
targeting PPIs as a therapeutic strategy in
cancer is still in its infancy, and examples of
modulators of protein complexes as potential
therapeutic agents are few relative to the more
widely studied area of small-molecule enzyme
(e.g. kinase) inhibitors (Ref. 10). The reasons for
the dominance of kinase (and other enzyme)
inhibitors as targets for modern cancer
therapeutics are centred on the enzyme
substrate-binding site. In the case of enzyme
inhibition, the design methodology for these
compounds is well established, and active sites
are usually contained within deep clefts that
clearly define the ligand-binding site and
contain the critical amino acid residues required
for ligand interaction. Furthermore, all
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molecules in a biological system are bathed in an
aqueous environment, and enzyme active-site
clefts tend to shield binding sites from water
molecules that can otherwise hinder ligand
interactions.
Small-molecule drug discovery against
protein–protein targets is more challenging
than for conventional small-molecule protein
targets but represents an innovative direction
for 21st century medicine. Although the field
has already been the subject of several reviews
(for a selection see Refs 1, 2, 3, 4, 5, 6, 7, 8, 9), in
this article we aim to give a broad overview of
emerging small-molecule PPI inhibitors in the
anticancer field.
The concept of protein–protein interaction
and ‘hot spots’
Among the reasons for the lack of modulators of
protein complexes as therapeutic agents has been
the notion that protein interfaces represent
difficult or intractable targets because of the
generally large and noncontiguous nature of
PPI surfaces. This perceived problem is
compounded by the lack of high-throughput
screening technologies and paucity of small
molecules in compound libraries with the size
and functionality to modulate protein-complex
targets selectively. In recent years, however,
several reports have appeared that challenge
the dogma that PPIs represent difficult targets
to modulate using small molecules. In
particular, the concept of PPI ‘hot spots’ has
aided the development of small molecules that
interact with a small area of an entire protein–
protein interface to exert high-affinity and
selective binding (Ref. 11).
The initial challenge in developing PPI
inhibitors is the discovery of specific PPIs and
in turn identification of those that are
‘druggable’. Two types of PPI can be defined:
transient and tight. Tight interactions can be
identified more easily, through biochemical
co-purification; in contrast, transient
interactions have been characterised by site-
directed mutagenesis and molecular modelling
as it is often difficult to co-crystallise transient
partners (Ref. 12). Computational techniques
have also been used to identify PPIs and their
inhibitors, and have been recently reviewed
(Ref. 13). Following the identification of a
suitable PPI, the next step involves study of the
binding interface and ligand design. This is also
challenging compared with designing a ligand
to interact with an active-site cleft. Interaction
sites are typically relatively flat with a large
surface area, although shallow grooves are
sometimes seen. Ligand-binding sites may be
exposed only after conformational changes
concomitant with binding of protein partners
(Ref. 14).
To understand better the nature of protein–
protein interfaces, a study of 75 PPIs
established a ‘standard size’ of 1600400 A˚2
for an interaction surface. The smallest
interfaces were approximately 1150 A˚2 and the
largest interfaces identified were up to 4660 A˚2
(Ref. 15). Given the large sizes involved, it
would be difficult to target a small molecule to
the whole interface. Similarly, large peptide-
based inhibitors can be less effective since a
single continuous peptide sequence may poorly
match the binding surface (Ref. 12).
Fortuitously, within a binding interface only a
small number of highly conserved amino acid
residues – ‘hot spots’ – are crucial for the
interaction, and thus these are often the target
for drug design. Hot spot residues within a
protein–protein interface are less obvious to
identify than, for example, important residues
within an enzyme active site. Although a
laborious process, site-directed mutagenesis has
been commonly employed to locate hot spot
residues, leading to a definition of a hot spot as
‘a residue that, when mutated to Alanine, gives
a distinct drop in the binding constant, typically
ten-fold or higher’ (Ref. 16). Phage display has
also been used to detect hot spots (Ref. 17).
Based on the analysis of currently identified hot
spots, the amino acids tryptophan (Trp), tyrosine
(Tyr) and arginine (Arg) occur frequently, often
surrounded by hydrophobic regions. These
amino acids are thought to exclude solvent
from the important interacting residues and are
favoured as they can form multiple interactions.
For example, despite structural similarity,
phenylalanine is three times less likely to occur in
a hot spot than Tyr, presumably due to the ability
of Tyr to form an additional hydrogen bond.
Hot spots contain leucine, methionine, serine,
threonine and valine residues less frequently
(Ref. 11). However, a review of the
thermodynamic aspects of PPIs concludes
that hydrophobic interactions are also a key
driving force for PPIs, and that the complex
thermodynamics of PPIs are ultimately a function
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of how protein–protein binding changes the
internal structure of the molecule(s) (Ref. 18).
Scope of the review
Over the past decade, the principal exploitation of
PPIs has been through therapeutic antibodies,
such as Herceptin, which are showing great
promise as a new class of drugs in cancer
treatment (Ref. 19). Therapeutic antibodies are
large proteins that interact directly, for example,
with membrane-bound receptor proteins, such
as growth factor receptors, to elicit a biological
response. Although an important class of cancer
therapeutic agents exploiting protein–protein
recognition, therapeutic antibodies (or other
‘biologics’) are not included in this review;
instead, we discuss the emerging class of small-
molecule inhibitors of PPIs, focusing on their
application to anticancer therapy. We consider
established clinical agents that fall into the PPI
modulator class (such as tubulin inhibitors), but
concentrate on agents in preclinical
development (such as the p53–MDM2
inhibitors). The mechanism of action of small-
molecule PPI inhibitors differs from that of the
antibodies in that a small, nonphysiological
compound designed to bind preferentially to a
PPI site blocks the binding of a further protein,
preventing the formation of a protein dimer/
multimer that would otherwise be essential for
regulating a biological process.
Protein–protein interactions as
therapeutic targets in cancer
Microtubules
One of the most successful therapeutic targets
in cancer treatment is tubulin. There are
several natural, semisynthetic and synthetic
compounds that have significant clinical
activity by affecting tubulin PPIs. They have
been extensively reviewed elsewhere (Refs 20,
21, 22, 23), but we summarise the topic here
for completeness.
Microtubules are large cylindrical proteins –
25 nm in diameter and up to several mm in
length (Ref. 21). A microtubule is composed of
copolymers of two monomers – a- and
b-tubulin – binding in an alternating manner.
Microtubules undergo constant dynamic
polymerisation and depolymerisation at both
ends of the filament (referred to as plus and
minus ends), although the process is faster at
the plus end (Refs 20, 21, 24). Microtubule
dynamicity is required for several biological
processes including maintenance of cell shape,
cellular signalling and movement; however,
their best-studied role is in cell division
(Ref. 21). Several drugs exert their antitumour
effect by interfering with tubulin PPIs and are
classified according to the site to which they
bind on microtubules.
A crystal structure of the taxane analogue
taxol (a natural product from the Pacific yew
tree Taxus brevifolia) bound to tubulin indicates
that it binds within a hydrophobic pocket. It is
suggested that taxol stabilises microtubules
by strengthening PPIs, thus inhibiting cell
division (Ref. 20). Several synthetic taxane
derivatives are under clinical investigation. In
addition, nontaxane compounds are known to
bind at the taxane site and several are under
preclinical investigation, including the
epothilones (Ref. 25), eleutherobins (Ref. 26),
discodermolides (Ref. 27), sarcodicyins and
laulimalides (Ref. 21).
By contrast to taxol, colchicine (a natural
product from the plant genus Colchicum) and its
analogues destabilise microtubules. Although
the crystal structure of the tubulin–colchicine
complex is not available, studies suggest that
colchicine interacts with b-tubulin at the
interface between two tubulin monomers
(Refs 28, 29, 30).
Vincristine and vinblastine (natural products
from the periwinkle plant Catbaranthus roseus),
and new-generation analogues vinflunine and
vinorelbine, also destabilise microtubules
(Ref. 31). Vinblastine has been shown to interact
with b-tubulin (Refs 20, 23, 32). Other natural
products, including rhyzoxin, cryptophycins
and dolastatin 10, have similar effects to the
vincas (Ref. 33).
p53
The tumour suppressor protein p53, known
informally as ‘the guardian of the genome’, has
been extensively studied in the field of cancer.
It protects biological tissues from malignant
transformation and forms a central part of the
DNA-damage response. It is estimated that
around 50% of all human tumours have
mutations in the p53 gene (TP53), implying that
cancer cells sustain viability by reducing the
biological activity of p53 (Refs 34, 35, 36).
Human p53 contains 393 amino acids arranged
in four functional domains. The N-terminus
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interacts positively with transcription machinery
and with MDM2, an E3 ubiquitin ligase. The
second domain constitutes the DNA-binding
region, and harbours 90% of the reported p53
mutations. The third domain is responsible for
the formation of the p53 tetramer. The current
model of p53 function suggests that DNA
interactions occur with a tetramer form of p53
(actually a dimer of a dimer) (Refs 34, 36, 37).
Several events are known to induce the activity
of p53, including DNA damage, hypoxia,
oncogene overexpression and viral infections
(Refs 36, 38, 39). Numerous biological functions
have been attributed to p53 such as apoptosis
(Refs 40, 41) and senescence (Ref. 42), G1 arrest,
cell cycle control, DNA repair (Ref. 43) and
angiogenesis inhibition. Among the most
important of these functions is apoptosis
(programmed cell death), a conserved process
that mediates the elimination of a cell upon
exposure to genomic stress. The complete
mechanism through which p53 mediates
apoptosis is still under study; it is mediated
primarily but not exclusively by p53. Following
a stressful event, p53 activates through its
N-terminus many pro-apoptotic genes such as
POXA and PUMA. Another suggested
mechanism is linked to the mitochondria,
whereby p53 binds to the mitochondrial
membrane resulting in the formation of pores
and the release of cytochrome c; this in turn
activates caspases, which degrade the nucleus
resulting in cell death (Refs 44, 45).
Under normal conditions, cellular levels of
p53 are barely detectable: it has a short half-life
of 10–20 min as a result of a PPI with MDM2
that results in the negative regulation of p53
(Fig. 1) (Refs 34, 35). MDM2 catalyses the binding
of ubiquitin to p53, thereby directing it to
degradation by the proteasome (Ref. 46). In a
typical feedback loop, p53 increases the
transcription of MDM2 (Ref. 47). Under stressful
conditions, p53 concentrations are increased due
to a reduction in its MDM2-mediated degradation
and a concurrent increase in p53 transcription.
As increased p53 activity has an antitumour
effect, there have been many attempts to elevate
the biological activity of p53 by increasing its
accumulation in the cell. The main strategies
employed have been stabilisation of p53 or
protection from ubiquitination and proteasomal
degradation, primarily by blocking the p53–
MDM2 interaction (Refs 48, 49, 50). Close
examination of the p53–MDM2 interface
reveals that it is the side chains of only three
key p53 amino acids that make most of the
interactions within a hydrophobic groove in
the surface of MDM2 (Figs 1 and 2). In an
X-ray-crystallography-derived model of the
p53–MDM2 interaction shown in Figure 2a, a
p53-derived peptide (green) is shown
complexed with an MDM2 fragment (surface
render) containing the hydrophobic binding
cleft. The p53 fragment forms an a-helix from
which the side chains of the three amino acids
Leu26, Trp23 and Phe19 (shown left to right)
project into the binding cleft, promoting the
p53–MDM2 interaction (Refs 51, 52). Further
analysis of this hot spot revealed that the area
of the interaction site is about 300 A˚2 (Ref. 50)
The hot spot is a good target for drug design –
the strategy being to design a drug that mimics
the conformation and interaction of the three
p53 residues.
Small-molecule inhibitors of p53 PPIs
Although a p53–MDM2 PPI inhibitor has yet to
reach clinical trials, several small-molecule
inhibitors with significant potency have been
reported in the literature. Most of these
molecules are useful experimental tools for
research. Chalcones (compounds derived from
1,3-diphenylprop-2-en-1-one) were early-
reported molecules with such activity. They
interfere with p53–MDM2 interactions by
binding to the p53 transactivation domain with
relatively low potency: IC50s were in the range
50–250 mM (IC50 is the concentration of inhibitor
required to achieve 50% inhibition) (Ref. 53).
The natural product chlorofusin is a fungal
metabolite containing a peptide segment that
was discovered by screening over 53 000
microbial extracts. It inhibits the p53–MDM2
interaction with an IC50 of 4.6 mM; however, it is
a large (molecular weight of 1363.7),
structurally complex molecule that is less
practical for drug development or clinical use
than a smaller molecule (Ref. 54). A more drug-
like molecule called RITA (‘reactivation of p53
and induction of tumour cell apoptosis’)
(Fig. 3a) was similarly discovered by screening
a molecular library against cancer cell lines. It
too has micromolar potency and was reported
to interfere with p53–MDM2 interactions by
binding to p53 (Ref. 55), although more-recent
nuclear magnetic resonance (NMR) studies
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argue that RITA does not in fact block p53–MDM2
binding in vitro (Ref. 56).
The nutlins are a series of highly promising
molecules for p53–MDM2 inhibition and were
discovered by high-throughput screening
followed by structure-based optimisation (for
an example structure, see Fig. 3b). The nutlins
interfere with p53–MDM2 interactions by
mimicking the interaction of the three p53
residues within the MDM2 hot spot (Fig. 1),
and are highly potent (activities range between
100 and 300 nM). The interaction of nutlin
inhibitors with MDM2 has been studied using
X-ray crystallography (Fig. 2b): the imidazoline
substituents of the nutlin inhibitor occupy
similar regions within the binding cleft as the
p53 side chains (Refs 50, 57).
The BCL2 family
The B-cell lymphoma 2 (BCL2) family of proteins
is composed of more than 20 members (Refs 58,
59, 60). Some members are anti-apoptotic
[e.g. BCL2, BCL2L1 (Bcl-xL), BCL2L2 and
MCL1], whereas others are pro-apoptotic [e.g.
BAX, BAK1, BID and BCL2L11 (BIM)]. The
family members cooperate through PPIs to
mediate the intrinsic apoptotic pathway
(Refs 61, 62). Anti-apoptotic BCL2 family
members protect cells from apoptosis by
inhibiting the action of pro-apoptotic members
(Ref. 63). Three-dimensional NMR studies of
anti-apoptotic BCL2 proteins revealed the
presence of a hydrophobic groove that acts as a
binding site for the BH3 peptide domain of pro-
apoptotic BCL2 members (Ref. 64). Agents
designed to target the binding grooves of anti-
apoptotic BCL2 proteins are predicted to induce
apoptosis in cancer cells (which overexpress
these anti-apoptotic proteins) by antagonising
their protective effect.
Over the past ten years, several nonpeptidic
small-molecule inhibitors to anti-apoptotic
BCL2 proteins have been introduced and
some of them are already in clinical trials as
A conceptual diagram of a protein–protein interaction (PPI) inhibitor targeting a 
PPI (p53–MDM2) hot spot
Expert Reviews in Molecular Medicine © 2008 Cambridge University Press
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Figure 1. A conceptual diagram of a protein–protein interaction (PPI) inhibitor targeting a PPI
(p53–MDM2) hot spot. In this diagram, the inhibition of the p53–MDM2 interaction by a nutlin inhibitor is
used as an example to illustrate the generic concept of the action of all PPI inhibitors discussed in this
article, since it is one of the best-characterised examples of PPI inhibition. MDM2 normally negatively
regulates the antitumour protein p53 by inducing its proteasomal degradation; however, in response to
cellular stress, particularly DNA damage, p53 levels rise as a result of increased p53 transcription and
reduced MDM2-mediated degradation (not shown). The nutlin inhibitors are similarly thought to increase p53
levels, by blocking MDM2-mediated degradation. The PPI of p53 and MDM2 is mediated by the side chains
of three p53 amino acids (Leu, Trp and Phe) that are recognised by MDM2. The nutlin inhibitors mimic the
binding of these amino acid side chains and preferentially bind to MDM2. This physically blocks the
interaction of the two proteins, thus releasing p53 that is free to exert a beneficial antitumour effect. This
schematic illustration is derived from the X-ray data presented in Fig. 2a, and comparison of Figs 1 and 2a
should be instructive. Abbreviation: MDM2, ‘mouse double minute 2’ homologue.
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single-agent chemotherapy. For example, GX015-
070(Obatoclax) isasmall-molecule BCL2inhibitor
developed by Gemin X Biotechnologies Inc.
currently being tested in multiple Phase I and
Phase II clinical trials against both solid tumours
and haematological malignancies (Ref. 66). The
development of BCL2-modulatory small
molecules as potential anticancer therapeutics
has been reviewed in recent years (for examples,
see Refs 65, 66), and discussion here is limited to
two examples that have pioneered interest in
this field and provided a proof-of-principle for
inhibition of BCL2 PPIs as a viable therapeutic
strategy in cancer.
Small-molecule inhibitors of BCL2 PPIs
ABT-737 (Fig. 3c) was discovered by high-
throughput NMR-based screening of a chemical
library to identify small molecules that bind to
the BH3-binding groove of BCL2L1 (Ref. 66).
ABT-737 was found to bind to BCL2, BCL2L1
and BCL2L2 with high affinity (Ki  1 nM).
ABT-737 did not itself induce release of
cytochrome c from mitochrondria, but inhibited
BCL2 protection at concentrations 10 nM by
blocking the inhibition of BID-mediated
cytochrome c release through binding to the
BH3-binding groove of BCL2. This binding
disrupted the PPI between BCL2L1 and pro-
apoptotic BCL2 proteins.
ABT-737 was found to be active both as a single
agent or when used in combination with other
chemotherapies or radiation, where it reduced
the EC50 (the half maximal effective
concentration – the concentration that produces
a 50% effect compared with the maximum) of
several antitumour agents by 50% or more. As a
single agent, it displayed potent cytotoxicity in
several lymphomas and small-cell lung cancer
(SCLC), where it had an EC50 of 0.13–0.85 mM
Figure 2. Structural analysis of the interactions of
MDM2withp53andwithanutlin inhibitor. (a)X-ray
crystallographic models of the p53–MDM2
interaction (Ref. 51). A fragment of MDM2 is
shown rendered as a solvent-accessible solid
surface and coloured by atom type (carbon, grey;
oxygen, red; nitrogen, blue; sulphur, yellow). The
p53 fragment is rendered as a green ribbon
showing only the side-chains of Leu26, Trp23 and
Phe19 rendered as sticks and coloured by atom
type (carbon, green; nitrogen, blue). These three
nonpolar side-chains project into a hydrophobic
(i.e. predominantly carbon-containing) pocket in
the surface, thus stabilising the interaction
between p53 and MDM2. (b) X-ray crystal
structure of the MDM2–nutlin-inhibitor complex
(Ref. 57). The MDM2 fragment is again shown as a
solvent-accessible solid surface, from a similar
perspective. Binding to the hydrophobic pocket is
a nutlin inhibitor, rendered as sticks and coloured
by atom type (carbon, green; nitrogen, blue;
oxygen, red; bromine, purple). Note that the
hydrophobic (i.e. mostly carbon-containing)
groups project into the binding pocket, mimicking
the p53 side-chains and that additional groups in
the nutlin inhibitor form further interactions.
Abbreviation: MDM2, ‘mouse double minute 2’
homologue.
Expert Reviews in Molecular Medicine 
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Figure 2. Structural analysis of the interactions of
MDM2 with p53 and with a nutlin inhibitor. (See
next column for legend.)
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Chemical structures of protein–protein interaction (PPI) inhibitors
Expert Reviews in Molecular Medicine © 2008 Cambridge University Press
NO2
S N
CH3
CH3
S
O
O
O
N
N
Cl
N
O N
NH
N
O
Cl
Cl
OCH3
O
CH3
CH3
H
N
O
N
OH
N
O
N
H
CH3
H3C
N
H
O
HN
CONH2
N
H
O
HN
H3C
OR
O
CO2H
HO2C
O
O
HO
HO
O
N
H
HN
CONH2
O
N
H
O
P
O
HO
HO
H3C
N
H
HO
OH
CH3
O
F
CO2H
O
CH3
H3COS
CH3
CO2H
F
H
N O
O
N
SS
OHHO O
N
N
O
OH
H
P
c ABT-737
BCL2 PPI inhibitor
a RITA
b Nutlin 3 
        p53–MDM2 inhibitor
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Figure 3. Chemical structures of protein–protein interaction (PPI) inhibitors. (See next page for legend.)
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when used in lymphoma cell lines carrying the
t(14:18) chromosomal translocation. As an
inhibitor of anti-apoptotic BCL2, ABT-737
exhibited pro-apoptotic activity and induced
apoptosis in a concentration-dependent manner
in patient-derived chronic lymphocytic B-cell
leukaemia cells. In vivo, ABT-737 caused
complete regression of established SCLC
tumour xenografts as a result of apoptotic cell
death. ABT-737 induced apoptosis selectively in
cancer cells without affecting normal cells,
where a significant increase in caspase-3 was
noticed in tumour cells but not in liver, heart or
intestinal normal cell lines (Ref. 67).
Peptide inhibitors of BCL2 PPIs
The concept of hydrocarbon-stapled helical
peptides that bind with increased affinity
to protein targets such as BCL2 has recently
been pioneered; these ‘stapled’ peptides
provide enhanced protease-resistance and cell
permeability compared with their nonstapled
counterparts. The chemical ‘stapling’ strategy
involves the insertion of a,a-disubstituted
non-natural amino acids containing side-chains
with an olefinic terminus at two carefully
chosen peptidic positions to flank either three
or six amino acids. The chemoselective
ruthenium-catalysed olefin metathesis reaction
was used to ‘staple’ together the two alkene
tethers to provide peptides that maintain
helical structure, but with enhanced stability.
A stapled peptide of the BH3 domain from
the pro-apoptotic BID protein was found to
specifically activate the apoptotic pathway
to kill leukaemia cells, and inhibit the growth
of human leukaemia xenografts in vivo
(Ref. 68).
XIAP–DIABLO
‘Inhibitors of apoptosis proteins’ (IAPs) are
endogenous caspase inhibitors that bind and
inhibit caspases-3, -7 and -9. Eight members of
the IAP family are known so far (Ref. 69), of
which X-linked inhibitor of apoptosis protein
(XIAP) is the best characterised in terms of its
inhibitory mechanism. XIAP has three BIR
domains (BIR-1–3) and a RING finger that
binds and inhibits caspases through specific
PPIs (Ref. 70). The BIR-3 domain of XIAP
inhibits caspase-9, while BIR-1 and -2 are more
specific for caspases-3 and -7 (Refs 71, 72, 73).
Endogenous inhibition of the IAP family can
occur via DIABLO (also known as Smac), a
protein released from the mitochondria in
response to apoptotic stimuli, which directly
interacts with XIAP (Refs 72, 73). This, together
with the finding that the levels of different IAP
family members were elevated in several
tumours, indicated the possibility of targeting
the IAP family to induce apoptosis and treat
cancer (Refs 74, 75, 76). More-recent studies in
this area have focused on the role of TNF-a
signalling in mediating apoptotic cell death,
since IAP antagonists were found to induce
TNF-a-dependent apoptosis (Refs 77, 78, 79).
Since small-molecule inhibitors of XIAP have
been recently reviewed (Refs 80, 81), we will
focus here on one relevant example from the
group of compounds derived from DIABLO
Figure 3. Chemical structures of protein–protein interaction (PPI) inhibitors. (Legend; see previous page
for figure.) (a) RITA is a simple and potentially drug-like thiophene-furan-thiophene derivative. (b) The nutlin
series of MDM2–p53 PPI inhibitors is exemplified here by nutlin 3; the dihydroimidazole core (i.e. the central
five-membered nitrogen-containing ring) is fixed and variation is introduced within the substituents – for
example, nutlin 3 is a chlorine analogue. (c) ABT-737 is a prototypical compound of the PPI inhibitors that
target anti-apoptotic BCL2 family members. (d) This inhibitor of the anti-apoptoic XIAP is a tripeptide
composed of alanine, an unnatural cyclohexyl amino acid and proline; the N-terminus is modified with a
methyl group and the C-terminus is modified with a bulky tetrahydronapthalene derivative. (e–g) The
structures of these GRB2 SH2 inhibitors clearly show the b-turn-like nature of these compounds. Note the
addition of a restraining olefin (double bond) bridge in (g). (h) This Raf–Raf inhibitor is derived from the
nonsteroidal anti-inflammatory drug sulindac (i); both structures are provided to show the comparison. (j)
FJ9 is a small-molecule indole-based inhibitor of the interaction between the receptor FRZ-7 and the PDZ
domain of DVL, thereby inhibiting oncogenic WNT signalling. (k) ICG-001 is a small molecule that
downregulates b-catenin–TCF signalling by specifically binding to the coactivator CBP. Abbreviations:
BCL2, B-cell lymphoma 2; CBP, cyclic AMP response element-binding protein; DVL, dishevelled; FRZ,
frizzled; GRB2, growth factor receptor bound protein 2; MDM2, ‘mouse double minute 2’ homologue; SH2,
Src-homology 2; TCF, T-cell factor; WNT, ‘wingless-type MMTV integration site family’; XIAP, X-linked
inhibitor of apoptosis protein.
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peptides (DIABLO ‘mimetics’) that inhibit the
interaction between the BIR-3 domain of XIAP
and DIABLO. DIABLO-mimetic XIAP inhibitors
act by binding more strongly to the BIR-3
domain of XIAP, inhibiting the caspase binding
to XIAP at this site; they thus antagonise the
inhibitory effect of XIAP and induce apoptosis.
For example, a series of tripeptides that bind to
the XIAP BIR-3 domain with nanomolar
affinities have been reported (Ref. 82). The most
active compound of the series (Fig. 3d) showed
a wide range of potencies against a diverse
panel of human cancer cell lines, with the
highest activity (nanomolar EC50) against the
human breast cancer cell lines BT-549 and
MDA-MB-231, the melanoma cell line SK-MEL-
5, and the acute promyelocytic leukaemia cell
line HL-60. Interestingly, there was no
correlation between the potency of this
compound and the expression of XIAP.
Measuring caspase-3 activation in MDA-
MB-231 cells treated with the tripeptide
showed an up to eightfold increase in caspase-3
activity in a dose-dependent manner. Apoptosis
was induced by the tripeptide in the absence of
an identified apoptotic stimulus. In vivo testing
(MDA-MB-231 flank breast cancer xenograft
model) showed that a 20 mg/kg/day dose of
the compound inhibited tumour growth rate by
50–60%.
SH2 domains
Many membrane-associated proteins are coupled
to kinases, and their activation is essential for
cellular signalling. Src-homology 2 (SH2)
domains are noncatalytic, highly conserved
domains of approximately 100 amino acids that
are an essential feature in many cellular
signalling proteins: they recognise hot spots
that contain a phosphorylated tyrosine residue
and adjacent residues, facilitating the assembly
of transient protein pairs that subsequently
participate in signal transduction. One of the
best-studied SH2 domains is that of growth
factor receptor bound protein 2 (GRB2). GRB2
links signalling from receptor proteins to the
RAS signal transduction pathway, ultimately
controlling the mitogen-activated protein
(MAP) kinase cascade. This important
regulatory pathway is vital for cell division and
an excellent target for novel cancer therapies
(Refs 83, 84). Increased GRB2 SH2 signalling is
seen in cancer, and so inhibiting the PPI
between GRB2 and tyrosine-phosphorylated
signalling proteins will have antiproliferative
effects. Several tyrosine-containing, peptide-
based inhibitors have been reported but have
stability and delivery problems. However,
compounds containing a phosphorylated
tyrosine residue were shown to be optimal for
potent PPI inhibition. The development of
nonpeptide small-molecule inhibitors has been
reported; the phosphorylated compound in
Figure 3e represents a typical member of a
series of compounds designed to inhibit Grb2
SH2 PPIs (Ref. 85).
However, the phosphotyrosine group of this
compound led to practical difficulties, and a
bioisosteric replacement of the phosphate group
was investigated to improve the stability/
delivery profile of this class of compounds.
When the phosphate group was replaced
with a dicarboxylic acid (Fig. 3f), reasonable
activity was retained, suggesting that a similar
number of hydrogen bonds with the target
protein were formed. Related compounds
within this series were shown to penetrate
cells and inhibit downstream MAP kinase
activation, establishing good rationale for these
compounds as potential cancer therapeutics
(Ref. 86). Their potency is believed to be related
to the ability to mimic secondary structure
elements in the PPI. Several PPI hot spots have
been found in b-turns (Ref. 87), and the Grb2
SH2 domain recognises a phosphorylated
tyrosine hot spot that adopts the conformation
of a b-turn. The cyclohexyl amino acid residue
in this inhibitor series (Fig. 3e–g) helps to
restrain the molecule in a similar, b-turn-like
conformation (Ref. 88). The concept has been
extended with the addition of an olefin (i.e.
carbon–carbon double bond) link (Fig. 3g) to
further stabilise the b-turn conformation by
incorporating it into a macrocyclic ring. This
compound produced a 100-fold enhancement in
terms of binding to the protein target, but no
cellular activity was observed (Refs 89, 90).
The RAS–RAF interaction
RAS is a GTPase important to several signal
transduction cascades. Normally, RAS binds
to RAF, a kinase that subsequently activates the
MAP kinase signalling pathway that is an
important proliferative pathway in the cell.
RAS is mutated and hence deregulated in
approximately 30% of human cancers (Ref. 91).
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Inhibitors of the RAS–RAF interaction are thus
likely to block cell division and be of interest in
anticancer therapeutics. Small-molecule
inhibitors have been identified – notably a
furano-indene derivative (Fig. 3 h). This
compound was derived by rational medicinal
chemistry from a metabolite of the nonsteroidal
anti-inflammatory drug (NSAID) sulindac
(Fig. 3i), following the observation that it had
anticancer properties associated with the RAS
pathway. Although inhibition of the RAS–RAF
interaction by this compound was modest
(IC50 ¼ 30 mM), this simple small molecule
provides a significant advance over previous
attempts to disrupt the interaction (Refs 6, 92).
Related investigations reported that a 28 amino
acid peptide comprising the hot spot region of
RAS inhibited the RAS–RAF interaction with
an improved IC50 of 3 mM. However, although
an order of magnitude less active, the
nonpeptide, sulindac-derived inhibitor (Fig. 3 h)
remains a more drug-like molecule better suited
for further development (Ref. 93).
WNT pathway PPI targets
Multiple mechanisms activate the WNT
signalling pathway in cancer. For example, in
response to WNT ligands, inactivation of
GSK-3b leads to inhibition of degradation of
the b-catenin-turnover complex, leading to
inappropriate transcriptional activation.
Inappropriate activation of the WNT pathway is
associated with stimulation of proliferation and
prevention of apoptosis in a number of human
cancers (Ref. 94), and the discovery of inhibitors
of WNT pathway PPIs is a growing area of
interest. Two PPI targets within the WNT
signalling pathway are considered here, where
small-molecule inhibitors with antitumour
properties have been described.
Frizzled–Dishevelled
The Frizzled (FRZ)–Dishevelled (DVL)
interaction is of crucial importance in relaying
WNT signalling to the b-catenin-turnover
complex. Different WNT signalling molecules
use different subtypes of FRZ receptor.
Particularly promising with respect to cancer
drug design is the observation that WNT
signalling via FRZ-7 is associated with
oncogenesis, and FRZ-7 is reported to be
overexpressed in both tumour cell lines and
tumour tissues. FRZ-7 interacts directly with
the PDZ domain of the DVL family of proteins
(overexpressed in a variety of cancer cells);
hence specific interference of the FRZ-7–DVL
PPI could represent a promising target for
cancer therapy. A small-molecule inhibitor (FJ9;
Fig. 3j) of the interaction between FRZ-7 and
the PDZ domain of DVL has been identified,
which was able to suppress b-catenin-
dependent tumour cell growth (Ref. 95).
Significant antitumour effects of FJ9 were
observed, including induction of apoptosis in
human cancer cell lines and in vivo inhibition
of tumour growth of mouse xenograft (H460)
models. FJ9 is one of the first small-molecule
inhibitors to show antitumour activity through
selective inhibition of PPIs mediated by PDZ
domains.
b-Catenin–CBP
Mutations in one of the components of the
b-catenin complex regulated by WNT signalling,
the adenomatous polyposis coli (APC)
gene product, occur in most colon cancers
and lead to inappropriate activation of b-catenin-
responsive genes in colon cancer. b-catenin
regulates transcription in a complex with T-cell
factor (TCF), whose formation involves the
coactivator cyclic AMP response element-
binding protein (CBP). ICG-001 (Fig. 3 k) is a
small molecule that downregulates b-catenin–
TCF signalling by specifically binding to CBP.
ICG-001 was also found to selectively induce
apoptosis in transformed (but not normal)
colon cells, and have in vitro activity in colon
carcinoma cells (growth reduction and
induction of apoptosis). Notably, ICG-001 was
also found to have efficacy in the Min mouse
and nude mouse xenograft models of colon
cancer (Ref. 96).
Summary and conclusions
The study of PPIs has gathered considerable pace
in recent years. Initial experimental difficulties
have been overcome and practical applications,
for example drug design, can now be
considered. Drug design has traditionally been
directed towards well-characterised targets,
such as enzyme active sites; however, a greater
understanding of PPIs and how to target them
is opening up new horizons in the future of
drug development. A large number of diseases
could potentially be treated by PPI inhibition
due to the myriad PPIs that occur within the
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cell. Progress in the cancer arena has been
particularly strong. In most cases PPI inhibition
has provided an alternative approach to exploit
an existing, known target. However, it seems
highly likely that entirely novel PPI-unique
therapeutic targets may soon emerge. Many
of the early successes targeting PPIs involved
the use of peptide inhibitors, but peptides
(and large molecules, such as chlorofusin,
with molecular weights .500) have poor
bioavailability and are generally unsuitable as
drug molecules. Although it initially appeared
unlikely that small molecules could successfully
inhibit PPIs the findings reviewed in this article
clearly demonstrate that low molecular weight
compounds can successfully block PPIs and
thus represent a new emerging class of
therapeutic agents.
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Further reading, resources and contacts
For general information on all aspects of cancer (science, treatment and research) visit:
http://www.cancerresearchuk.org/
http://www.cancerhelp.org.uk/
All published protein structures, including several discussed in this article, are available for viewing, download
and information at the protein databank:
http://www.rcsb.org/pdb
A protein–protein interaction Wikibook (a free, open content textbook that anyone can edit) can be viewed at:
http://en.wikibooks.org/wiki/Proteomics/Protein_-_Protein_Interactions
Commercial websites containing information relating to compounds reported in this article:
http://www.geminx.com (Phase 2 clinical trial of GX015-070 small-molecule BCL2 inhibitor)
http://www.roche.com/ (Developing the p53–MDM2 inhibitors; detailed presentation at
http://www.roche.com/med_mb200605lv.pdf)
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